NEW YORK ─ Shares of several in vitro diagnostic companies plummeted on Monday following an announcement that a vaccine developed by Pfizer and BioNTech demonstrated 90 percent efficacy in a clinical study at protecting people from COVID-19.
Shares of Quidel, Fulgent Genetics, Fluidigm, Meridian Bioscience, and GenMark Diagnostics were among those that slid sharply after the vaccine announcement.